{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:02Z","timestamp":1789603802528,"version":"build-2803163510"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Hypophysitis occurs in up to 10% of patients treated with immune-checkpoint inhibitors (ICIs). MRI shows no abnormalities of the pituitary gland in one third of patients. A delayed diagnosis increases the risk for life-threatening adrenal crisis, underscoring the need for early detection. This study evaluates the diagnostic accuracy FDG PET\/CT in detecting ICI-induced hypophysitis in a cohort of melanoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>Patients with metastatic melanoma and ICI-induced hypophysitis, who underwent FDG PET\/CT 90 days before to 10 days after diagnosis, were compared with an age- and sex-matched control group of patients undergoing ICI treatment without signs of hypophysitis. The ratio of SUV<jats:sub>max<\/jats:sub> of the pituitary gland to the SUV<jats:sub>mean<\/jats:sub> of the blood pool (target-to-background ratio [TBR]) was calculated. Diagnostic accuracy of the TBR was assessed using area under the receiver operating characteristics curve analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 28 patients was included. The majority of patients with hypophysitis received ipilimumab\/nivolumab (64.3%, 9\/14). Visual assessment of the TBR distribution demonstrated a positive correlation with decreasing time to diagnosis. To evaluate diagnostic performance, only patients with FDG PET\/CT 50 days before to 8 days after diagnosis (11\/14) were included. TBR was significantly higher in these compared with the control group (median [interquartile range], 2.78 [2.41] vs 1.59 [0.70], respectively; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.034). A sensitivity of 72.7% and a specificity of 90.9% were achieved at a TBR threshold of 2.41 (area under the receiver operating characteristics curve = 0.769).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings suggest that, in patients undergoing ICI treatment for metastatic melanoma, a pituitary TBR of approximately 2.4 may indicate impending ICI-induced hypophysitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005440","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T16:04:27Z","timestamp":1727366667000},"page":"e656-e663","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["18F-FDG PET\/CT for Detection of Immunotherapy-Induced Hypophysitis\u2014A Case-Control Study"],"prefix":"10.1097","volume":"49","author":[{"given":"Alessa","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Mart\u00ednez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Erlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Messerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Huellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Skawran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","year":"2020","journal-title":"Target Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","year":"2022","journal-title":"Ann Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","year":"2019","journal-title":"Horm Metab Res"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","year":"2018","journal-title":"Eur J Cancer"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2019.06.020","article-title":"Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy","volume":"119","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.crad.2020.12.028","article-title":"The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients","volume":"76","year":"2021","journal-title":"Clin Radiol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO guidelines committee","volume":"31","year":"2020","journal-title":"Ann Oncol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s12094-022-02840-9","article-title":"Diagnostic impact of 18F-FDG PET\/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy","volume":"24","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41598-019-57313-x","article-title":"Increased 18F-FDG signal recovery from small physiological structures in digital PET\/CT and application to the pituitary gland","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"55544","DOI":"10.18632\/oncotarget.15417","article-title":"Evaluation of pituitary uptake incidentally identified on 18F-FDG PET\/CT scan","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","year":"2016","journal-title":"J Clin Endocrinol Metabol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/RLU.0b013e3182639765","article-title":"Detection of early onset of Hypophysitis by 18F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1295865","DOI":"10.3389\/fendo.2023.1295865","article-title":"Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis","volume":"14","year":"2023","journal-title":"Front Endocrinol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","article-title":"Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT","volume":"24","year":"2017","journal-title":"Acad Radiol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:05:43Z","timestamp":1750532743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005440","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}